Meeting Coverage > > ASH: Hematology– More than half of kids in research study had no cured bleeds at follow-up of more than 100 weeks
by Mike Bassett, Staff Writer, MedPage Today December 10, 2023
SAN DIEGO– Administering emicizumab (Hemlibra) to formerly without treatment or minimally dealt with babies with serious hemophilia A without element VIII inhibitors works and safe, according to arise from research study provided here.
The stage III HAVEN-7 research study revealed that at a typical follow-up of 101.9 weeks, the annualized cured bleeding rate was 0.4 (95% CI 0.30-0.63) amongst 55 research study individuals, with 30 kids (54.5%) having no cured bleeds, reported Steven Pipe, MD, of the University of Michigan in Ann Arbor.
The annualized bleeding rate for all bleeds was 2.0 (95% CI 1.49– 2.66), without any cured spontaneous bleeds.
“This was over an average follow up of over 100 weeks, and the average age was 29 months– so these are absolutely activated young children through this scientific cut-off date.” Pipeline stated throughout a press instruction at the yearly conference of the American Society of Hematology, “Emicizumab prophylaxis truly showed constant effectiveness throughout all the bleeding endpoints.”
For years the method to handling hemophilia has actually been using prophylactic aspect VIII protein with aspect VIII focuses.
